195results about How to "Rapid drug release" patented technology

A coating on a balloon of a medical device is provided. The coating comprises a drug and a polymer. Also provided are methods of forming and using the coating.

Controlled-release dosage formulations including at least one compound of Formulae I to XXVIII herein and a controlled-release carrier and methods of treatment using the same are provided.

The present invention relates to an oral pharmaceutical composition in particle form, which comprises particles that contain a drug at the core of the pharmaceutical composition in particle form; a middle layer that contains two types of water-soluble components, an insolubilizer and an insolubilizing substance; and an outer layer for controlling water penetration that contains a water-insoluble substance. The present invention makes it possible to provide a pharmaceutical composition in particle form for oral use with which initial drug release is suppressed, the drug is quickly released thereafter, and lag time can be controlled as needed, and fast-disintegrating tablets containing this composition.

The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms. In one of the embodiments, the sustained release composition combines an antihistamine, an antitussive and a decongestant. The invention further provides for methods of making and using such formulations.

Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

The invention belongs to the field sustained/controlled-release preparations, in particular to an oral sustained/controlled-release pellet combination containing ginkgo biloba extract and a preparation method. The oral sustained/controlled-release pellet combination is composed of (A) a core containing a pill; (B) an insulating coating layer; (C) a sustained-release coating layer; (D) and an enteric-coated coating layer. The invention is the traditional Chinese medicine multi-component sustained-release pellet combination which is taken once by 24 hours and the multi-unit sustained-release pellet combined preparation with the different drug release systems, the core containing the pill is prepared by adopting the extrusion pill rolling method, a novel sustained-release multi-layer coating technology and a fluidized bed are utilized for coating the sustained-release pellet, the rapid-release part and the sustained-release part of the coated pellet are mixedly filled into a hard capsule or pressed into a pellet tablet. The sustained-release pellet has stable coating process and good reproducibility, thereby being applicable to the industrial mass production; and the drug quality of the preparation is stable through the long-term storage. The in vitro release test shows that the multiple components of the traditional Chinese medicine can achieve the sustained-release role, the sustained-release preparation can significantly increase the transmembrane absorption and the stability of various effective active ingredients by oral drug administration, the curve of plasma drug concentration in vivo is smooth, and the design purpose of 24-hour sustained-release is achieved.

The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains 1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate, 2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active ingredient from the release-controlled part B).

The present invention discloses coating compositions with taste masking property, comprising a blend of pH sensitive polymers and optionally a pH independent polymer or a blend of the pH sensitive polymer and pH independent polymer used for taste masking of highly bitter drugs. The pH sensitive polymers used comprise the acid soluble polymers and the enteric polymers. The process for the preparation of taste masked pharmaceutical compositions of the bitter drugs comprising the said coating compositions is disclosed. The concomitant use of the polymers inhibits the release of the bitter drug at the pH of saliva. The said coating compositions deliver substantial amount of the bitter drug immediately with improved palatability.

The present invention discloses compositions, comprising a lipid-polymer matrix to mask the bitter or unpleasant taste of the medicament. The lipid or a blend of lipids, are used in combination with the pH dependent polymer where the said polymer is acid soluble or swellable The process for the preparation of taste masked pharmaceutical compositions of the bitter drugs comprising the said lipid-polymer compositions are disclosed. The concomitant use of the acid soluble polymer, which remains collapsed at the pH of saliva, inhibits the release of drug at that pH and hence they further help in bitterness inhibition. The said compositions deliver substantial amount of the bitter drug immediately at the gastric pH with improved palatability.

The invention provides a mussel mucoprotein gel for wound repair, and a preparation method and an application thereof. The mussel mucoprotein gel for wound repair comprises the following raw materials in percentage by weight: 0.15-0.2% of mussel mucoprotein, 0.1-5% of protein protector, 0.1-5% of tackifier, 0.1-5% of stabilizer, 0.1-5% of preservative, 1-10% of wetting agent, 0.1-5% of pH (potential of hydrogen), and 64.8-98.35% of medical dissolving water. With Carbomer as a substrate, the mussel mucoprotein gel has good extending property, is easy to coat and adhere on a skin, has no irritation to skin and mucosa and can absorb tissue penetrating fluid, so secretions can be exhausted conveniently; the gel is not greasy, the medicines are released fast, and the coupling effect with skin tissues is excellent.

The invention relates to plant mass cement for manufacturing hollow capsules of foods, medicines and the like, and a hollow capsule which is prepared from the plant mass cement and can be quickly disintegrated. The plant mass cement for preparing the hollow capsule is prepared by mixing the following components in percentage by weight: 12-25 percent of hydroxypropyl methyl cellulose, 0.1-9 percent of hydroxypropyl starch or acidified hydroxypropyl starch, 0.4-2 percent of a gelatinizing agent and the balance of water, wherein the aqueous solution of the 2wt% hydroxypropyl starch at 20 DEG C has a viscosity of 3-7mpa.s; the substitution degree DS of the hydroxypropyl starch or acidified hydroxypropyl starch is in a range of 0.004-0.55. The plant mass cement is prepared by adopting a conventional capsule preparation process for preparing the hollow capsule can be used for preparing a hydroxypropyl methyl cellulose hollow capsule which can be quickly disintegrated.

The invention discloses a zwitter-ion-contained multiple acid-sensitive anti-tumor drug-loading micelle, and a preparation method and an application thereof, and belongs to the field of biological materials. The zwitter-ion-contained multiple acid-sensitive anti-tumor drug-loading micelle comprises a zwitter-ion hydrophilic shell and a lyophobic core containing two acid-sensitive bonds. The method includes the steps: separating methanol from hydroxyethyl acrylate and 2,2-dimethoxypropane and synthesizing 2,2-di(acryloyloxy-1-oxethyl) propane by an alcohol exchange method; connecting open-loop beta-propiolactone with 2-(dimethylamino) ethyl methacrylate to synthesize carboxybetaine methacrylate; obtaining a carboxybetaine methacrylate monomer polymer by an atom transfer free radical polymerization method; synthesizing triblock amphiphilic polymers by the atom transfer free radical polymerization method and a Michael addition one-pot method, and preparing the drug-loading nano-micelle by an ultrasonic drop method and a dialysis method. By aid of the drug-loading micelle, anti-tumor effects of chemotherapeutic drugs can be improved.

The invention belongs to the technical field of medicines, and relates to a redox sensitive albumin binding prodrug with a series of tumor tissue specific responses. The albumin binding prodrug is ananti-tumor drug-maleimide molecule prodrug particularly including three docetaxel-maleimide small molecule prodrugs; by utilizing a maleimide ring in a prodrug structure as a target head of plasma albumin 34-bit free sulfydryl in a binding body, so that after a drug enters into a body through intravenous injection, the drug is quickly and specifically bound with albumin to form an albumin-drug composition; therefore, the drug stability is enhanced, the circulation time of the drug in the boy is obviously prolonged, and accumulation of the drug on tumor tissues is realized by utilizing an EPR (Enhanced Permeability and Retention) effect. In addition, in the prodrug structure, by using a redox sensitive key as a binding key, quick release of the drug in tumor cells is promoted, a toxic effect of the drug on normal cells also can be alleviated, the prodrug has high selectivity, the aims of increasing an effect and reducing the toxicity of docetaxel are fulfilled, and a greater market application prospect is achieved.

Enteric coated capsules or tablets for oral delivery of a protein, polypeptide or peptide drug, in particular for oral delivery of insulin, are provided, comprising microparticles of the protein, polypeptide or peptide drug, microparticles of a protease inhibitor and, optionally, microparticles of an absorption enhancer. The protease inhibitor and the absorption enhancer may be together in the same microparticles. The microparticles of each component are embedded in an enteric polymer matrix. The enteric coated tablet or capsule of the invention enables fast release of the protein, polypeptide or peptide drug at different times at desired loci in the gastrointestinal tract

A pharmaceutical tablet composition comprising irbesartan and lactose, said composition being essentially free of surfactant.

An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable ion-exchange matrix and a water-soluble electrolytic drug associated with the ion-exchange matrix, wherein the surface charge of the ion-exchange matrix is opposite that of the electrolytic drug wherein the dispersed phase further comprises a non-electrolytic, soluble component having low molecular weight and a diffusion controlling membrane and a dispersion medium substantially free of diffusible counterions, further comprising an excipient capable of associating with water and impeding water activity such that drug dissolution is inhibited prior to administration. The invention also provides methods for preparing such compositions and methods of treatment.

The invention relates to a taste-masked donepezil cyclodextrin inclusion compound and an oral instant membrane containing the same, belonging to the technical field of medicine. The oral instant membrane comprises the donepezil cyclodextrin inclusion compound, a film-forming material, a plasticizer, a disintegrating agent and other excipients. Specifically, the oral instant membrane is prepared by including donepezil free alkali in cyclodextrin or a derivative thereof, then dissolving the excipients such as the film-forming material in distilled water, adding an appropriate amount of the donepezil cyclodextrin inclusion compound and preparing a homogeneous solution. The donepezil cyclodextrin inclusion compound provided by the invention completely masks the bad taste of donepezil; the oral instant membrane prepared from the donepezil cyclodextrin inclusion compound has good taste, is rapid in drug release and greatly improves patient compliance; moreover, the taste-masked donepezil cyclodextrin inclusion compound can be applied to other oral dosage forms such as tablets and solutions.

The invention relates to an application of a pH-sensitive coaxial polylactate caprolactone PLCL/gelatin double drug-loaded fiber scaffold, namely the application of the pH-sensitive coaxial polylactate caprolactone PLCL/gelatin double drug-loaded fiber scaffold as a tissue engineering scaffold. The fiber scaffold with a drug controlled release function has good biocompatibility, is degradable, has pH sensitivity and good mechanical property and can play roles in diminishing inflammation and resisting cancers.